A Phase 2b, Randomised, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Tolerability of 3 Dose Levels of NMD670 over 21 Days in Adult Patients with AChR/MuSK-Ab+ Myasthenia Gravis

Status

Recruiting

Phases

Phase 2

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2023-507539-40-00

Acronym

NMD670-02-0002

Enrollment

Registered

2024-06-17

Start date

2024-07-19

Completion date

Unknown

Last updated

2025-11-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Myasthenia Gravis

Brief summary

Change from baseline to day 21 in quantitative myasthenia gravis (QMG) total score for NMD670 vs placebo

Interventions

DRUGNMD670

DRUGPlacebo

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
Change from baseline to day 21 in quantitative myasthenia gravis (QMG) total score for NMD670 vs placebo	—

Countries

Belgium, Denmark, France, Italy, Netherlands, Poland, Spain

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026